Targeting mTOR Shows Promise in Cutaneous Sarcoidosis Targeting mTOR Shows Promise in Cutaneous Sarcoidosis

Vienna researchers reported that 7 of 10 patients treated with systemic sirolimus had noted improvements in skin lesions, which continued for up to 2 years of follow-up.Medscape Medical News
Source: Medscape Rheumatology Headlines - Category: Rheumatology Tags: Rheumatology Source Type: news